-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Centogene (NASDAQ:CNTG) Increases By 45.3%
Short Interest in Centogene (NASDAQ:CNTG) Increases By 45.3%
Centogene (NASDAQ:CNTG – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 32,700 shares, a growth of 45.3% from the August 15th total of 22,500 shares. Currently, 0.5% of the company's stock are short sold. Based on an average daily trading volume, of 20,000 shares, the days-to-cover ratio is presently 1.6 days.
Centogene Stock Down 2.0 %
Shares of NASDAQ CNTG traded down $0.03 during midday trading on Friday, hitting $1.39. 2,349 shares of the company's stock were exchanged, compared to its average volume of 25,374. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.48 and a quick ratio of 2.41. Centogene has a twelve month low of $1.19 and a twelve month high of $11.09. The company has a market cap of $37.67 million, a PE ratio of -0.57 and a beta of -1.19. The firm's fifty day simple moving average is $1.61 and its 200-day simple moving average is $2.69.
Get Centogene alerts:Centogene (NASDAQ:CNTG – Get Rating) last issued its earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. The business had revenue of $11.59 million for the quarter. Research analysts predict that Centogene will post -1.72 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, SVB Leerink decreased their price objective on Centogene from $10.00 to $6.00 and set an "outperform" rating for the company in a research note on Monday, July 18th.Institutional Investors Weigh In On Centogene
An institutional investor recently bought a new position in Centogene stock. DekaBank Deutsche Girozentrale bought a new position in shares of Centogene (NASDAQ:CNTG – Get Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 16,319 shares of the company's stock, valued at approximately $67,000. DekaBank Deutsche Girozentrale owned approximately 0.08% of Centogene as of its most recent filing with the SEC.
Centogene Company Profile
(Get Rating)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Recommended Stories
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.
Centogene (NASDAQ:CNTG – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 32,700 shares, a growth of 45.3% from the August 15th total of 22,500 shares. Currently, 0.5% of the company's stock are short sold. Based on an average daily trading volume, of 20,000 shares, the days-to-cover ratio is presently 1.6 days.
世紀新紀元(納斯達克:CNTG-GET評級)是空頭股數8月份大幅增長的目標。截至8月31日,空頭股數共有32,700股,比8月15日的22,500股增長了45.3%。目前,該公司0.5%的股票被賣空。以日均成交量2萬股計算,目前天數與回補比率為1.6天。
Centogene Stock Down 2.0 %
Centogene股價下跌2.0%
Shares of NASDAQ CNTG traded down $0.03 during midday trading on Friday, hitting $1.39. 2,349 shares of the company's stock were exchanged, compared to its average volume of 25,374. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.48 and a quick ratio of 2.41. Centogene has a twelve month low of $1.19 and a twelve month high of $11.09. The company has a market cap of $37.67 million, a PE ratio of -0.57 and a beta of -1.19. The firm's fifty day simple moving average is $1.61 and its 200-day simple moving average is $2.69.
上週五午盤,新浪納斯達克股價下跌0.03美元,至1.39美元。該公司股票成交量為2,349股,而其平均成交量為25,374股。該公司的債務權益比為0.67,流動比率為2.48,速動比率為2.41。Centogene的12個月低點為1.19美元,12個月高位為11.09美元。該公司市值為3767萬美元,市盈率為-0.57,貝塔係數為-1.19。該公司的50日簡單移動均線為1.61美元,200日簡單移動均線為2.69美元。
Centogene (NASDAQ:CNTG – Get Rating) last issued its earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. The business had revenue of $11.59 million for the quarter. Research analysts predict that Centogene will post -1.72 EPS for the current fiscal year.
Centogene(納斯達克代碼:CNTG-GET Rating)最近一次發佈財報是在7月15日(星期五)。該公司公佈了本季度每股收益(0.54美元)。Centogene的淨資產回報率為負134.55%,淨利潤率為負35.35%。該業務本季度的收入為1159萬美元。研究分析師預測,Centogene本財年的每股收益將達到1.72歐元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Institutional Investors Weigh In On Centogene
機構投資者參與世紀新紀元
An institutional investor recently bought a new position in Centogene stock. DekaBank Deutsche Girozentrale bought a new position in shares of Centogene (NASDAQ:CNTG – Get Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 16,319 shares of the company's stock, valued at approximately $67,000. DekaBank Deutsche Girozentrale owned approximately 0.08% of Centogene as of its most recent filing with the SEC.
一家機構投資者最近買入了Centogene股票的新頭寸。根據德意志銀行在提交給美國證券交易委員會的最新的Form 13F文件中,該公司在第一季度購買了Centogene(CNTG-GET Rating)的新股票頭寸。該公司購買了16,319股該公司股票,價值約6.7萬美元。截至Centogene最近向美國證券交易委員會提交的文件,德意志銀行持有Centogene約0.08%的股份。
Centogene Company Profile
Centogene公司簡介
(Get Rating)
(獲取評級)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Centogene N.V.及其子公司專注於罕見疾病,將現實世界的臨牀和基因或其他數據轉換為可操作的信息,供世界各地的患者、醫生和製藥公司使用。它通過三個部門運作:製藥、診斷和新冠肺炎測試。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- 免費獲取StockNews.com關於Centogene的研究報告(CNTG)
- 第四季度值得考慮的3家銀行
- 股市:紅海中的三座強國
- 沒有人告訴這三隻股票這是下跌的一週
- MarketBeat:回顧一週9/12-9/16
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.
接受《世紀英文報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Centogene和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧